| 1173 |
Duties and responsibilities of the LT at the DMC |
English |
Not specified |
|
Off |
| 1172 |
Precautions to Ensure Reliability of a Test for Diagnosis of DR-TB |
English |
Not specified |
|
Off |
| 1171 |
Aims and Objectives of Screening for Active TB |
English |
Not specified |
|
Off |
| 1170 |
Importance of Properly Identifying Presumptive TB Cases |
English |
Not specified |
|
Off |
| 1169 |
Patient Provider Support Agency [PPSA]: A Multipronged Approach to Engage the Private Sector |
English |
Not specified |
|
Off |
| 1168 |
Recording and Reporting at Ayushman Bharat Health and Wellness Centres |
English |
Not specified |
|
Off |
| 1167 |
Roles of Accredited Social Health Activist [ASHA] for TB Service Delivery at ABHWCs |
English |
Not specified |
|
Off |
| 1166 |
District TB Centre and its Functions |
English |
Not specified |
|
Off |
| 1165 |
Functions of District National Health Mission |
English |
Not specified |
|
Off |
| 1164 |
End TB Strategy Approach |
English |
Not specified |
|
Off |
| 1163 |
Universal Access to Quality TB Care |
English |
Not specified |
|
Off |
| 1162 |
Quality Assurance of Anti-TB Drugs |
English |
Not specified |
|
Off |
| 1161 |
Preventive Treatment for Contacts of DR-TB Patients |
English |
Not specified |
|
Off |
| 1160 |
Need for Palliative Care in DR-TB Patients |
English |
Not specified |
|
Off |
| 1159 |
Flow Chart of MDR/RR-TB Patients on Shorter Oral Bedaquiline-containing Regimen from Diagnosis to Treatment Outcome |
English |
Not specified |
|
Off |
| 1158 |
Flow Chart of H Mono/Poly DR-TB Patients from Diagnosis to Treatment Outcome |
English |
Not specified |
|
Off |
| 1157 |
Interim Treatment Outcomes of DR-TB Cases |
English |
Not specified |
|
Off |
| 1156 |
Severity Criteria for Reporting ADRs |
English |
Not specified |
|
Off |
| 1155 |
Causality Assessment: WHO-UMC [UPSALA Monitoring Centre] Causality Categories for ADR Reporting |
English |
Not specified |
|
Off |
| 1154 |
Causality Assessment for ADR Reporting |
English |
Not specified |
|
Off |
| 1153 |
Methods for Pharmacovigilance Activity Reporting [aDSM] |
English |
Not specified |
|
Off |
| 1152 |
Adverse Drug Events: H Mono/Poly DR-TB Regimen |
English |
Not specified |
|
Off |
| 1151 |
Use of Isoniazid [H] Mono/Poly DR-TB Regimen in Special Situations |
English |
Not specified |
|
Off |
| 1149 |
Replacement Sequence in the H Mono/Poly DR-TB |
English |
Not specified |
|
Off |
| 1148 |
Regimen, Duration and Dosage for Isoniazid [H] Mono/Poly DR-TB Regimen |
English |
Not specified |
|
Off |
| 1147 |
Isoniazid [H] Mono/Poly DR-TB Regimen: Pre-treatment Evaluation |
English |
Not specified |
|
Off |
| 1146 |
Adverse Drug Reactions due to Longer oral M/XDR-TB Regimen |
English |
Not specified |
|
Off |
| 1145 |
Use of Longer Oral M/XDR-TB Regimen in Severe Forms of Extrapulmonary TB and TB Meningitis |
English |
Not specified |
|
Off |
| 1144 |
Pre-treatment Evaluation [PTE] in Longer Oral M/XDR-TB Regimen |
English |
Not specified |
|
Off |
| 1143 |
Use of M/XDR-TB Regimen in People Living with HIV [PLHIV] |
English |
Not specified |
|
Off |
| 1142 |
Clinical Monitoring of DR-TB Patients |
English |
Not specified |
|
Off |
| 1141 |
Rapid Molecular Drug-resistance Testing |
English |
Not specified |
|
Off |
| 1140 |
DR-TB Service Referral Linkages Scenario: DR-TB Patient Referred for Treatment from the Private Sector with Treatment Initiated in the Private Sector |
English |
Not specified |
|
Off |
| 1139 |
DR-TB Service Referral Linkages Scenario: DR-TB Patient Referred for Treatment from the Private Sector with Bacteriological Confirmation in the Private Sector |
English |
Not specified |
|
Off |
| 1138 |
DR-TB Services Referral Linkage Scenario: Patient Notified from the Private Sector |
English |
Not specified |
|
Off |
| 1137 |
Requirements from Institutions for the Establishment of Nodal DR-TB Centre |
English |
Not specified |
|
Off |
| 1136 |
Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Eligibility Criteria |
English |
Not specified |
|
Off |
| 1135 |
Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Treatment Extension |
English |
Not specified |
|
Off |
| 1134 |
Shorter oral Bedaquiline-containing MDR/RR-TB regimen |
English |
Not specified |
|
Off |
| 1133 |
Prevention of Drug-resistance |
English |
Not specified |
|
Off |
| 1132 |
Baseline Second-line Drug-susceptibility Testing |
English |
Not specified |
|
Off |
| 1131 |
Pre-treatment Counselling |
English |
Not specified |
|
Off |
| 1130 |
Causes for Drug-resistant Tuberculosis |
English |
Not specified |
|
Off |
| 1129 |
Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Pre-treatment Evaluation [PTE] |
English |
Not specified |
|
Off |
| 1128 |
Newer Anti-TB Drugs: Delamanid [Dlm] |
English |
Not specified |
|
Off |
| 1126 |
Newer Anti-TB Drugs: Bedaquiline [Bdq] |
English |
Not specified |
|
Off |
| 1125 |
Newer Anti-TB Drugs |
English |
Not specified |
|
Off |
| 1123 |
Treatment Adherence for individuals taking TPT |
English |
Not specified |
|
Off |
| 1122 |
Follow-up Monitoring for individuals taking TPT |
English |
Not specified |
|
Off |
| 1076 |
Weight Band-wise Dosages of DR-TB Drugs for Adults |
English |
Not specified |
|
Off |
